Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET

Rhea-AI Summary

Vaccinex, Inc. (Nasdaq: VCNX) announced that Dr. Maurice Zauderer and Dr. Elizabeth Evans will present at the Jefferies Healthcare Conference on June 10, 2022, at 10:30 a.m. ET. They will update investors on progress in phase 2 trials for their lead product, pepinemab, targeting head and neck cancer and Alzheimer’s disease. One-on-one meetings will occur from June 8 to 10. Pepinemab aims to inhibit SEMA4D to prevent immune infiltration in tumors and inflammation in chronic brain diseases, with ongoing studies for Huntington’s disease development.

ROCHESTER, N.Y., May 25, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer, along with Elizabeth Evans, Ph.D., Chief Operating Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time. The Company will provide an update on enrollment in phase 2 trials of its lead product in Head and Neck Cancer and in Alzheimer’s disease. Interested investors are invited to participate in one-on-one meetings, June 8 to 10.

Jefferies Healthcare Conference (in-person) Details:
Date:		June 10, 2022
Presentation Time:		10:30 to 10:55 am ET
Webcast:		https://wsw.com/webcast/jeff240/vcnx/1868175
Replay Availability:		Until September 8, 2022

Please contact your Jefferies representative if you would like to schedule a one-on-one meeting during the conference, June 8 to 10, 8:00 am to 5:00 pm.

About Vaccinex, Inc.
Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and a Phase 1/2a study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. The Company additionally intends to leverage its proprietary drug discovery platform, ActivMAb^®, to create strategic collaborations, particularly by exploiting its unique capability to select high value antibodies against important multi-pass membrane receptors.

Forward Looking Statements
To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of our clinical trials of pepinemab in various indications, the use and potential benefits of pepinemab in Huntington’s and Alzheimer’s disease and other indications, and other statements identified by words such as “may,” “will,” “appears,” “expect,” “hope”, “planned,” “anticipate,” “estimate,” “intend,” “hypothesis,” “potential,” “suggest”, “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, the impact of the COVID-19 pandemic, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in the Company’s most recent year-end Annual Report on Form 10-K and subsequent filings with the SEC.

Investor Contact
John Mullaly
LifeSci Advisors, LLC
617-429-3548
jmullaly@lifesciadvisors.com

FAQ

What is Vaccinex's lead product and its focus?

Vaccinex's lead product is pepinemab, aimed at inhibiting SEMA4D to treat cancer and neurodegenerative diseases.

When will Vaccinex present at the Jefferies Healthcare Conference?

Vaccinex will present on June 10, 2022, at 10:30 a.m. ET.

What updates will be provided during the presentation?

Updates will be on the enrollment in phase 2 trials for pepinemab in head and neck cancer and Alzheimer’s disease.

How can investors schedule one-on-one meetings at the conference?

Investors can contact their Jefferies representative to schedule one-on-one meetings from June 8 to 10.

What is the significance of pepinemab in clinical trials?

Pepinemab is being evaluated for its potential to treat recurrent or metastatic head and neck cancer and Alzheimer's disease.